Emerging agents like PCSK9 inhibitors, bempedoic acid, and cyclodextrins hold promise for inclusion in future guidelines due to their unique benefits, such as the monthly dosing of PCSK9 inhibitors and the potential to delay CKD progression with cyclodextrins. This evidence concerns the gene PCSK9 and chronic kidney disease.